Roivant Sciences Ltd (ROIV) Stock Price, Quote & News

Company Profile

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythemat...

Industry: Biotechnology

Sector: Healthcare

Website: roivant.com

Address:

11-12 St. James's Square, Suite 1 3rd Floor, London, United Kingdom

JB6791 Dec. 3 at 8:54 PM

$ABUS tick tock $ROIV investor day coming up I have a feeling we get a share swap.

2 · Reply

BillionerOfKing Dec. 3 at 4:23 PM

$ROIV Current Stock Price: $20.67 Contracts to trade: $20 ROIV Dec 19 2025 Call Entry: $0.80 Exit: $1.57 ROI: 97% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

judgeyoung2 Dec. 3 at 4:04 PM

$ROIV Roivant will also host an Investor Day on December 11, 2025

0 · Reply

BEATOFtheMARKET Dec. 2 at 4:41 PM

$ROBN $ROBT $ROIV $ROK $ROKU Cycle Trading Signal plugged into AI Lists 🔥 Undeniable Accuracy 🔥 Nothing More Accurate 🔥

0 · Reply

Alfalcon Nov. 26 at 7:27 PM

$ABUS our daddy $ROIV been rippen last 5 months. 😘 The 20 ma

1 · Reply

MichaelKTrades Nov. 25 at 9:44 PM

Biotech- Health care theme is still hot, most of my current ideas picked up here. $ROIV $TVTX- big accumulation, bull flag higher lows supported by the 10D MA

1 · Reply

BEATOFtheMARKET Nov. 23 at 5:25 PM

$ROBN $ROBT $ROIV $ROK $ROKU 🔥

0 · Reply

MyBrokenBus Nov. 20 at 5:18 PM

$ROIV I sold this in the 18's thinking it was running too fast, with too high an RSI. Then moved my money into stocks that have fallen like a rock over the last month. Don't be like me.

3 · Reply

J_Wayne Nov. 20 at 11:22 AM

$ROIV must be something good happening…it appears the first shit-bird has arrived 😆

2 · Reply

TickrTalk0007 Nov. 19 at 7:01 AM

$ROIV doofus CEO saying the stock is too high aka too long of fall 😂

0 · Reply

Roivant Sciences Ltd. (ROIV) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 13, 2025, 7:28 AM EST - 21 days ago

Roivant Sciences: Brepocitinib And Roadmap Still Underpriced

Nov 11, 2025, 10:31 AM EST - 23 days ago

Roivant Sciences Ltd. (ROIV) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript

Nov 10, 2025, 12:31 PM EST - 24 days ago

Roivant Sciences Ltd. (ROIV) Q2 2026 Earnings Call Transcript

Nov 10, 2025, 7:00 AM EST - 24 days ago

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update

Oct 27, 2025, 4:10 PM EDT - 5 weeks ago

Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

IMVT

Oct 27, 2025, 4:10 PM EDT - 5 weeks ago

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

Sep 25, 2025, 2:47 AM EDT - 2 months ago

Roivant Sciences Ltd. (ROIV) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript

Sep 24, 2025, 10:57 PM EDT - 2 months ago

Roivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2025 Transcript

Sep 23, 2025, 5:45 AM EDT - 2 months ago

Roivant Sciences Ltd. (ROIV) Q1 2024 Earnings Call Transcript

Sep 17, 2025, 3:43 PM EDT - 2 months ago

Roivant Sciences Ltd. - Special Call

Sep 17, 2025, 12:49 PM EDT - 2 months ago

Why Roivant Sciences Stock Is Soaring Today

Sep 17, 2025, 12:13 PM EDT - 2 months ago

Roivant/Priovant's Experimental Drug Shows Promise In Rare Skin Disease Trial

Sep 17, 2025, 8:21 AM EDT - 2 months ago

Roivant, Priovant Therapeutics' rare skin and muscle disease drug shows promise in trial

Sep 17, 2025, 7:00 AM EDT - 2 months ago

Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)

Sep 11, 2025, 4:30 PM EDT - 3 months ago

Roivant Named on Fortune Media and Great Place To Work's 2025 Best Workplaces in BioPharma List

Sep 8, 2025, 8:25 PM EDT - 3 months ago

Roivant Sciences Ltd. (ROIV) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 4, 2025, 7:00 AM EDT - 3 months ago

Pulmovant Receives Orphan Drug Designation in Japan for Mosliciguat for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

Sep 3, 2025, 11:07 PM EDT - 3 months ago

Roivant Sciences Ltd. - Immunovant Batoclimab Graves' Disease Proof-Of-Concept Study Remission Data Transcript

Sep 3, 2025, 1:01 PM EDT - 3 months ago

Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

Aug 15, 2025, 9:30 AM EDT - 3 months ago

Roivant Sciences: Vant Model And IMVT-1402 Create A 2025 Catalyst Stack

Aug 12, 2025, 6:42 PM EDT - 4 months ago

Why Roivant Sciences Stock Bounced Back on Tuesday

Aug 11, 2025, 4:58 PM EDT - 4 months ago

Why Roivant Sciences Stock Was Slipping on Monday

Aug 11, 2025, 12:28 PM EDT - 4 months ago

Roivant Sciences Ltd. (ROIV) Q1 2025 Earnings Call Transcript

Aug 11, 2025, 7:00 AM EDT - 4 months ago

Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update

Jul 28, 2025, 4:05 PM EDT - 4 months ago

Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025

Jun 16, 2025, 7:00 AM EDT - 6 months ago

Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics

Jun 9, 2025, 4:05 PM EDT - 6 months ago

Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis

May 29, 2025, 2:17 PM EDT - 6 months ago

Roivant Sciences Ltd. (ROIV) Q4 2024 Earnings Call Transcript

May 29, 2025, 7:00 AM EDT - 6 months ago

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update

May 15, 2025, 4:10 PM EDT - 7 months ago

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, May 29, 2025

Apr 23, 2025, 12:13 PM EDT - 8 months ago

Roivant Sciences: Primed For Growth With A De-Risked Pipeline

Apr 21, 2025, 7:00 AM EDT - 8 months ago

Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402

Mar 19, 2025, 7:45 AM EDT - 9 months ago

Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

Mar 18, 2025, 4:32 PM EDT - 9 months ago

Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

Mar 3, 2025, 9:15 AM EST - 9 months ago

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

ABUS

Feb 10, 2025, 12:32 PM EST - 10 months ago

Roivant Sciences Ltd. (ROIV) Q3 2024 Earnings Call Transcript

Feb 10, 2025, 9:33 AM EST - 10 months ago

Roivant Sciences Tops Q3 Expectations

Feb 10, 2025, 7:00 AM EST - 10 months ago

Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update

Feb 5, 2025, 12:12 PM EST - 10 months ago

Roivant: Telavant-Like Success Will Be Challenging To Replicate (Rating Downgrade)

Feb 3, 2025, 7:00 AM EST - 10 months ago

Zest Health Announces $13M in Funding to Curb Unnecessary Pharmaceutical Spend through High-Touch Care

Jan 29, 2025, 4:05 PM EST - 11 months ago

Roivant to Report Financial Results for the Third Quarter Ended December 31, 2024 and Provide Business Update on Monday, February 10, 2025

Jan 13, 2025, 9:00 AM EST - 11 months ago

Scipher Medicine and Roivant Partner to Bring Precision Medicine Insights to Rheumatology Drug Discovery and Development

Dec 4, 2024, 8:30 AM EST - 1 year ago

Roivant Sciences: A Biotech Growth Play With Major Ambitions

Dec 3, 2024, 7:19 AM EST - 1 year ago

Roivant's lung disease drug fails mid-stage trial

Nov 12, 2024, 2:41 PM EST - 1 year ago

Roivant Sciences Ltd. (ROIV) Q2 2024 Earnings Call Transcript

Oct 29, 2024, 4:35 PM EDT - 1 year ago

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024

Oct 22, 2024, 12:31 PM EDT - 1 year ago

Roivant Sciences: Good Value, But Near-Term Catalysts Could Bring Volatility

Sep 18, 2024, 3:20 PM EDT - 1 year ago

Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B

OGN

Sep 18, 2024, 10:59 AM EDT - 1 year ago

Roivant Flips a Skin Drug to Organon

OGN

JB6791 Dec. 3 at 8:54 PM

$ABUS tick tock $ROIV investor day coming up I have a feeling we get a share swap.

2 · Reply

BillionerOfKing Dec. 3 at 4:23 PM

0 · Reply

judgeyoung2 Dec. 3 at 4:04 PM

$ROIV Roivant will also host an Investor Day on December 11, 2025

0 · Reply

BEATOFtheMARKET Dec. 2 at 4:41 PM

$ROBN $ROBT $ROIV $ROK $ROKU Cycle Trading Signal plugged into AI Lists 🔥 Undeniable Accuracy 🔥 Nothing More Accurate 🔥

0 · Reply

Alfalcon Nov. 26 at 7:27 PM

$ABUS our daddy $ROIV been rippen last 5 months. 😘 The 20 ma

1 · Reply

MichaelKTrades Nov. 25 at 9:44 PM

Biotech- Health care theme is still hot, most of my current ideas picked up here. $ROIV $TVTX- big accumulation, bull flag higher lows supported by the 10D MA

1 · Reply

BEATOFtheMARKET Nov. 23 at 5:25 PM

$ROBN $ROBT $ROIV $ROK $ROKU 🔥

0 · Reply

MyBrokenBus Nov. 20 at 5:18 PM

$ROIV I sold this in the 18's thinking it was running too fast, with too high an RSI. Then moved my money into stocks that have fallen like a rock over the last month. Don't be like me.

3 · Reply

J_Wayne Nov. 20 at 11:22 AM

$ROIV must be something good happening…it appears the first shit-bird has arrived 😆

2 · Reply

TickrTalk0007 Nov. 19 at 7:01 AM

$ROIV doofus CEO saying the stock is too high aka too long of fall 😂

0 · Reply

BEATOFtheMARKET Nov. 17 at 2:18 PM

$ROIV $ROK $RPM $RRC $RSI

0 · Reply

CapitalismUSA Nov. 17 at 1:33 PM

$ROIV Time to buy ABUS….$25.

0 · Reply

DogshtTrading Nov. 14 at 10:09 PM

$ROIV posted this a year ago. Vivek got his… https://www.tradingview.com/chart/ROIV/lHQKa32P-VIVEK-S-SLUSH-FUND/

0 · Reply

Shortsales Nov. 14 at 8:17 PM

$ROIV $ABUS

2 · Reply

OptionRunners Nov. 13 at 8:03 PM

$ROIV Buyer of the February 20th 2026 $23 calls 5,000 times for $0.90-$0.95

0 · Reply

DocPharm Nov. 13 at 9:14 AM

$ROIV $ABUS 🆙⬆️↗️🔝

0 · Reply

Joe_Mama Nov. 12 at 1:34 PM

$ROIV Amazing defiance of daily and weekly RSI overbought conditions. This is why I remain long reguardless.

0 · Reply

JarvisFlow Nov. 11 at 8:00 PM

Citigroup has adjusted their stance on Roivant Sciences ( $ROIV ), setting the rating to Buy with a target price of 25 → 26.

0 · Reply

Alfalcon Nov. 10 at 6:23 PM

$ROIV

0 · Reply

Shortsales Nov. 10 at 4:54 PM

$ROIV $ABUS

1 · Reply

futurerobo34 Nov. 10 at 1:07 PM

$ROIV why such a big miss on revenue?

0 · Reply

DonCorleone77 Nov. 10 at 12:06 PM

$ROIV Roivant Sciences reports Q2 EPS (17c), consensus (30c) -- Q2 revenue $1.6M, consensus $6.92M. -- Sees cash runway into profitability. -- Consolidated cash, cash equivalents, restricted cash and marketable securities of $4.4 billion as of September 30, 2025, supporting cash runway into profitability.

0 · Reply

Market Cap	13.98B
Revenue (ttm)	29.05M
Net Income (ttm)	-171.98M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-592.01%
Debt to Equity Ratio	0.00

Volume	6,795,800
Avg Vol	7,777,524
Day's Range	N/A - N/A
Shares Out	695.49M
Stochastic %K	89%
Beta	1.22
Analysts	Strong Sell
Price Target	$24.55